Rhythm Pharmaceuticals
RYTM
74 hedge funds and large institutions have $851M invested in Rhythm Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 14 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
0.89% more ownership
Funds ownership: 91.11% → 92% (+0.89%)
5% less funds holding
Funds holding: 78 → 74 (-4)
6% less capital invested
Capital invested by funds: $908M → $851M (-$57.4M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.47M |
| 4 |
Janus Henderson Group
London,
|
+$5.87M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$8.21M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.65M |
| 4 |
PA
Perceptive Advisors
New York
|
-$4.28M |
| 5 |
O
OrbiMed
New York
|
-$3.12M |
RYTM Hedge Fund Activity: Q4 2018 in Review
74 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2018, worth a combined $851M — down 6.3% from $908M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RYTM and 10 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 31 added.
The largest buyer was BlackRock, adding an estimated $11.4M. The largest seller was Foresite Capital Management IV, cutting an estimated $8.21M.
- 74 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2018, down from 78 in Q3 2018.
- Funds reported $851M of Rhythm Pharmaceuticals stock for Q4 2018, down 6.3% quarter-over-quarter.
- 10 funds opened new Rhythm Pharmaceuticals positions in Q4 2018 and 14 closed out, a net change of -4 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2018 was BlackRock, an estimated $11.4M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2018 was Foresite Capital Management IV, an estimated $8.21M sold.
Based on aggregated 13F filings for Q4 2018.